

Anti-PILRA Reference Antibody (Denali patent anti-PILRA)

Catalog # APR11521

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9UKJ1
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-mut2
Calculated MW	34005

Additional Information



Target/Specificity	PILRA
Expression system	CHO

Protein Information


Name	PILRA
Function	Paired receptors consist of highly related activating and inhibitory receptors and are widely involved in the regulation of the immune system. PILRA is thought to act as a cellular signaling inhibitory receptor by recruiting cytoplasmic phosphatases like PTPN6/SHP-1 and PTPN11/SHP-2 via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. Receptor for PIANP.
Cellular Location	[Isoform 1]: Cell membrane; Single- pass type I membrane protein [Isoform 3]: Secreted.
Tissue Location	Predominantly detected in hemopoietic tissues and is expressed by monocytes, macrophages, and granulocytes, but not by lymphocytes. Also strongly expressed by dendritic cells (DC); preferentially by CD14+/CD1a- DC derived from CD34+ progenitors. Also expressed by CD11c+ blood and tonsil DC, but not by CD11c- DC precursors.

Images

Anti-PILRA Reference Antibody (Denali patent anti-PILRA) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-PILRA Reference Antibody (Denali patent anti-PILRA) is 95.3%, determined by SEC-HPLC.



PLVX-puro-PILRA-FL cell line were stained with Denali patent anti-PILRA and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 0.590 nM.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.